Literature DB >> 8109948

In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

S A Marshall1, R N Jones.   

Abstract

DU-6859a was tested against 844 recent clinical isolates (most from bacteremias) by using reference MIC determination procedures. The activity of DU-6859a against members of the family Enterobacteriaceae was comparable to that of ciprofloxacin (range of MICs for 90% of isolates [MIC90], < or = 0.015 to 1 microgram/ml), and the highest MICs were observed among Serratia marcescens and Providencia rettgeri isolates. The DU-6859a MIC90 for Pseudomonas aeruginosa and Xanthomonas maltophilia was 0.5 microgram/ml. Pneumococci (MIC90, 0.06 microgram/ml), Haemophilus influenzae (MIC90, < or = 0.004 microgram/ml), Moraxella catarrhalis (MIC90, < or = 0.015 microgram/ml), and pathogenic neisseriae (MIC90, 0.015 to 0.03 microgram/ml) were very susceptible to DU-6859a. All staphylococci had DU-6859a MICs of < or = 1 microgram/ml, including oxacillin- and ciprofloxacin-resistant strains. DU-6859a was very active against isolates resistant to ceftazidime (MIC90, < or = 0.12 microgram/ml), ciprofloxacin (MIC90, < or = 8 micrograms/ml), and gentamicin (MIC90, < or = 1 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109948      PMCID: PMC192801          DOI: 10.1128/AAC.37.12.2747

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Fluoroquinolone resistance. An evolving national problem or just a problem for some physicians?

Authors:  R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

Review 2.  New mechanisms of bacterial resistance to antimicrobial agents.

Authors:  G A Jacoby; G L Archer
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

3.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

4.  Resistance to ciprofloxacin appearing during therapy.

Authors:  N X Chin; N Clynes; H C Neu
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

5.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

  5 in total
  9 in total

1.  In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Molitoris; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid.

Authors:  J Child; D Mortiboy; J M Andrews; A T Chow; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

3.  In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

Authors:  D Milatovic; F J Schmitz; S Brisse; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

5.  Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.

Authors:  D M Citron; M D Appleman
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

6.  Disposition kinetics of levofloxacin in sheep after intravenous and intramuscular administration.

Authors:  Ayman Goudah; Sherifa Hasabelnaby
Journal:  Vet Med Int       Date:  2010-11-02

7.  MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 8.  In vitro activity of fluoroquinolones against gram-positive bacteria.

Authors:  G M Eliopoulos
Journal:  Drugs       Date:  1995       Impact factor: 9.546

9.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.